News

FDA Approves bluebird bio’s ZYNTEGLO®, the First Gene Therapy for People with Transfusion-Dependent Beta-Thalassemia

zynteglo approved for beta-thalassemia

bluebird bio, Inc. announced the FDA has approved ZYNTEGLO®, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell transfusions.

Read more


Cooley’s Anemia Foundation Named as One of the Beneficiaries of Savoy Foundation’s 25th Annual Savoy Ball Charity Gala

The event organizers are asking guests to help raise money for two selected charities: “Cooley’s Anemia Foundation” which funds medical research and education to benefit individuals living with the genetic blood disorder, thalassemia, and “A Chance in Life -The Village of Staten Island Program,” a US-based program in New York City for forgotten youth dedicated to providing shelter, education, and leadership development for at-risk youth.

Read more








Ralph Colasanti Elected National President of CAF

Ralph Colasanti

April 23, 2022 – History was made today at the annual board meeting of the Cooley’s Anemia Foundation (CAF) when Ralph Colasanti was elected the first person with thalassemia to serve as National President of the Foundation’s board of directors. The Foundation, which was started in 1954, is the primary voice for those with thalassemia, […]

Read more


ICER To Look at Gene Therapy for Thalassemia

The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of betibeglogene autotemcel (Zynteglo/LentiGlobin, bluebird bio) for the treatment of beta thalassemia. An FDA decision on betibeglogene autotemcel is expected in mid-2022.  ICER is inviting public comment on its initial Draft Scoping Document, which details […]

Read more


Secured By miniOrange